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Objectives: To evaluate the frequency of four serum biomarkers in RA patients and their
relatives and identify possible associations with clinical ﬁndings of the disease.
Design and methods: This was a transversal analytical study. Anti-cyclic citrullinated peptide
(anti-CCP), anti-mutated citrullinated vimentin (anti-MCV) and IgA-rheumatoid factor (RF)
were determined by ELISA and IgM-RF by latex agglutination in 210 RA patients, 198 relatives
and  92 healthy controls from Southern Brazil. Clinical and demographic data were obtained
through charts review and questionnaires.
Results: A higher positivity for all antibodies was observed in RA patients when compared
to  relatives and controls (p < 0.0001). IgA-RF was more frequent in relatives compared to
controls (14.6% vs. 5.4%, p = 0.03, OR = 2.98; 95% CI = 1.11–7.98) whereas anti-CCP was the
most common biomarker among RA patients (75.6%). Concomitant positivity for the four
biomarkers was more common in patients (46.2%, p < 0.0001). Relatives and controls were
mostly positive for just one biomarker (20.2%, p < 0.0001 and 15.2%, p = 0.016, respectively).
No  association was observed between the number of positive biomarkers and age of disease
onset, functional class or tobacco exposure. In seronegative patients predominate absence
of  extra articular manifestations (EAMs) (p = 0.01; OR = 3.25; 95% CI = 1.16–10.66). Arthralgia
was  present in positive relatives, regardless the type of biomarker.
Conclusions: A higher number of biomarkers was present in RA patients with EAMs. Positivity
of  biomarkers was related to arthralgia in relatives. These ﬁndings reinforce the link betweenPlease cite this article in press as: Nass FR, et al. Analysis of four serum biomarkers in rheumatoid arthritis: association with extra articular
manifestations in patients and arthralgia in relatives. Rev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.03.001
distinct biomarkers and the pathophysiologic mechanisms of AR.
©  2016 Elsevier Editora Ltda. All rights reserved.
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Análise  de  quatro  marcadores  sorológicos  na  artrite  reumatoide:
associac¸ão  com  manifestac¸ões extra-articulares  no  paciente  e  artralgia
em  familiares
Palavras-chave:
Artrite reumatoide
Fator reumatoide
Anti-CCP
Anti-MCV
Biomarcadores
r  e  s  u  m  o
Objetivos: Avaliar a frequência de quatro marcadores sorológicos em pacientes com AR e
familiares e identiﬁcar possíveis associac¸ões com achados clínicos da doenc¸a.
Métodos: Estudo analítico transversal. Determinaram-se os níveis de anticorpos
antipeptídeo citrulinado cíclico (anti-CCP), anticorpos antivimentina citrulinada-mutada
(anti-MCV) e fator reumatoide (FR) IgA por Elisa e de FR-IgM por aglutinac¸ão em látex em
210 pacientes com AR, 198 parentes e 92 controles saudáveis do sul do Brasil. Coletaram-se
dados clínicos e demográﬁcos por meio da revisão de prontuários e questionários.
Resultados: Observou-se maior positividade para todos os anticorpos em pacientes com
AR  em comparac¸ão com os familiares e controles (p < 0,0001). O FR-IgA era mais frequente
em familiares quando comparados com os controles (14,6% versus 5,4%, p = 0,03, OR = 2,98;
IC95% = 1,11 a 7,98). O anti-CCP foi o biomarcador mais comum entre pacientes com AR
(75,6%). A positividade concomitante para os quatro biomarcadores foi mais comum nos
pacientes (46,2%, p < 0,0001). Familiares e controles eram positivos em sua maioria para
apenas um biomarcador (20,2%, p < 0,0001 e 15,2%, p = 0,016, respectivamente). Não foi obser-
vada  associac¸ão entre o número de biomarcadores positivos e a idade de início da doenc¸a,
classe funcional ou exposic¸ão ao fumo. Em pacientes soronegativos, predominou a ausência
de  manifestac¸ões extra-articulares (MEA) (p = 0,01; OR = 3,25; IC95% = 1,16 a 10,66). A artralgia
estava presente em familiares positivos, independentemente do tipo de biomarcador.
Conclusões: Uma maior quantidade de biomarcadores estava presente em pacientes com AR
com  MEA. A positividade dos biomarcadores estava relacionada com a artralgia em famil-
iares. Esses achados reforc¸am a ligac¸ão entre os diferentes biomarcadores e os mecanismos
ﬁsiopatológicos da AR.
© 2016 Elsevier Editora Ltda. Todos os direitos reservados.
SubjectsIntroduction
Rheumatoid arthritis (RA) is a chronic inﬂammatory disease
that occurs in 0.2–1% of the world population.1 Its prevalence
in ﬁrst degree relatives of RA patients is of 2–4%, characterizing
them as a risk group for RA.2–5 In this context, investiga-
tion of serological markers in healthy relatives may be of
value to identify earlier cases of RA6,7 and to understand
the pathophysiologic mechanisms underlying the disease
process.
Rheumatoid factor (RF) is a classical serological marker
used for RA diagnosis, with IgM-RF being the most com-
mon isoform. In contrast, IgA-RF has been associated with
erosive arthritis and seems to be a better indicator of dis-
ease severity than IgM-RF or IgG-RF.8,9 Antibodies against
citrullinated peptides (ACPAs), such as anti-cyclic citrul-
linated peptide (anti-CCP) and anti-mutated citrullinated
vimentin (anti-MCV) are considered highly speciﬁc mark-
ers for RA.10 Anti-CCP has both diagnostic and prognostic
value and can be detected before clinical manifestations
of the disease.11 Recently, anti-MCV has also been pro-
posed as a diagnostic marker for early arthritis, with the
same speciﬁcity but higher sensitivity of anti-CCP.12 In addi-Please cite this article in press as: Nass FR, et al. Analysis of four serum 
manifestations in patients and arthralgia in relatives. Rev Bras Reumatol.
tion, anti-MCV has been detected in healthy relatives of
RA patients13 suggesting it as a novel prognostic marker
for RA.Positivity for more  than one RA serological marker in the
same patient may indicate worse prognosis or, in the case of
relatives, early disease onset.14,15 In fact, positivity for more
than one autoantibody has been reported among unaffected
relatives of RA patients, especially in families with multiple
cases.16,17
To date, there are no reports considering the simultaneity
of these biomarkers in RA patients and their relatives in the
Brazilian population. Thus, in the present work we  investi-
gated the frequency of anti-CCP, anti-MCV, IgA-RF and IgM-RF
in RA patients and their relatives, and tried to identify possi-
ble associations between the simultaneity of these biomarkers
and clinical ﬁndings or diagnosis of RA.
Design  and  methods
This was a transversal and analytical study approved by the
local Ethics Committee in Research. Informed consent was
obtained from all subjects.biomarkers in rheumatoid arthritis: association with extra articular
 2016. http://dx.doi.org/10.1016/j.rbre.2016.03.001
Two-hundred and ten adult RA patients meeting the ACR
classiﬁcation criteria18 from a single tertiary center were
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Table 1 – Demographic and clinical features of RA
patients.
% (N)
Mean age (years) 51.1  ± 11.8
Female 84.8 (178/210)
Age at disease onset – (years; median) 45.0 ± 12.8
Disease duration (years; median) 7.0 ± 8.5
Eurodescendents (auto declared) 72.8 (131/180)
Afrodescendents (auto declared) 26.7 (48/180)
Tobacco exposure 46.0 (87/189)
Functional class
Class I 47.4 (99/209)
Class II 37.7 (83/209)
Class III 10.5 (22/209)
Class IV 2.4 (5/209)
Extra articular manifestations
Rheumatoid nodules 8.9 (17/190)
Secondary Sjögren syndrome 30.2 (49/162)
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Fig. 1 – Positivity of biomarkers in the studied groups.
Patients: anti-CCP+ vs. IgA-RF+: p = 0.03; OR = 1.62; 95%
CI = 1.06–2.48. All other comparisons: p = ns. Relatives:
anti-CCP+ vs. IgA-RF+: p = 0.004; OR = 0.34; 95%
CI = 0.16–0.70. All other comparison: p = ns. Controls: all
comparisons p = ns. Relatives IgA-RF+ vs. Controls IgA-RF+:
p = 0.03; OR = 2.98; 95% CI = 1.11–7.98. All other
comparisons: p = ns. ns, not signiﬁcant.Pulmonary ﬁbrosis 8.6 (15/175)
onsecutively enrolled in the study from August 2007 to April
009. Demographic and clinical features from RA patients are
hown in Table 1.
A total of 198 relatives were investigated (61.1% female,
8.9% male; mean age 36.8 years; range 7–91 years, 94%
rst-degree), representing altogether 78 families (2.54 rela-
ives/family). Additionally, sera from 92 healthy volunteers
rom the same geographical area, matched for gender and
ge with patients, were used as controls (82.6% female, 17.4%
ale; mean age 45.8 years; range 23–81 years). None of controls
ad familial RA cases.
utoantibodies  evaluation
nti-CCP and IgA-RF were assessed by enzyme-linked
mmunosorbent assay (ELISA) from INOVA Diagnostics (San
iego, USA). Anti-MCV was determined using the ORGEN-
EC Diagnostika ELISA kit (Mainz, Germany). IgM-RF was
easured using latex agglutination test (BioSystems S.A.,
arcelona, Spain). Cut-off values were established according
o the manufacturer’s speciﬁcations.
ata  collection
emographic and clinical data from patients and relatives
ere obtained through medical record review and individual
tandard questionnaires applied by a rheumatologist at the
ime of enrollment (Tables 1 and 2). In RA patients the fol-
owing extra articular manifestations (EAM) were taken into
ccount: rheumatoid nodules, serositis, pericarditis, valvu-
ar disease, vasculitis, lung ﬁbrosis, pneumonitis, Felty’s
yndrome and secondary Sjögren syndrome. Steinbrocker
unctional classiﬁcation was applied in order to access the
xtent of physical disability in RA patients. Diagnosis of sec-Please cite this article in press as: Nass FR, et al. Analysis of four serum 
manifestations in patients and arthralgia in relatives. Rev Bras Reumatol. 
ndary Sjogren’s syndrome followed the American European
riteria.19 Clinical follow-up of the positive relatives has been
arried out for the median time of 7 years (range 2–8; IQR = 6–7
ears).Statistical  analyses
Statistical analyses were performed using GraphPad Prism 4.0
(GraphPad Software Inc., La Jolla, USA) and Statistic 5.5 (Stat-
Soft Inc., Tulsa, USA). Comparisons between autoantibodies
levels were done applying nonparametric Kruskal–Wallis or
Mann–Whitney tests. Chi-square and Fisher’s exact tests were
applied for the analyses of the positivity between groups.
Spearman’s test was used for correlation analysis. The signif-
icance level was set at 0.05.
Results
Prevalence  of  biomarkers  in  RA  patients,  relatives  and
controls
The prevalence of each biomarker in RA patients, their rela-
tives and controls can be seen on Fig. 1, where it can be noted
that the most prevalent biomarker in RA patients is anti CCP
and the most common in relatives was IgA RF.
The median titer of each biomarker was studied in the 3
groups and results are showed in Fig. 2 where it is possible to
see that relatives had an intermediate value between patients
and controls.
In RA patients a signiﬁcant correlation was observed
among the titers of the four investigated biomarkers, but
the correlation between anti-MCV and anti-CCP (r = 0.73), and
IgM-RF and IgA-RF (r = 0.71) were both stronger compared
to other associations (anti-MCV/IgM-RF, r = 0.38; anti-MCV/
IgA-RF, r = 0.41; IgM-RF/anti-CCP, r = 0.46; IgA-RF/anti-CCP,biomarkers in rheumatoid arthritis: association with extra articular
2016. http://dx.doi.org/10.1016/j.rbre.2016.03.001
r = 0.47).
The presence of the four biomarkers simultaneously posi-
tive in the RA group occurred in 46.2% while in the relatives it
was found in 2% and in none of controls.
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Table 2 – Association between demographic and clinical data and biomarkers in RA patients.
Number of positive biomarkers N (%) p
0 (n = 28) 1 (n = 15) 2 (n = 28) 3 (n = 42) 4 (n = 97)
Female gender 26/28 (92.8) 9/15 (60) 25/28 (89.3) 42/42 (100) 76/97 (78.4) 0.0006a
Age at disease onset (median) 18–75 (41.5; IQR 27.2–48.7) 24–69 (46.0; IQR 35.0–53.0) 19–69 (43.5; IQR 31.5–50.0) 18–83 (43.5; IQR 30–49.7) 16–71 (46; IQR 32.7–52.0) 0.50c
Age (mean) 48.2 ± 10.4 50.3 ± 12.9 50.1 ± 11.9 52.9 ± 13.79 51.7 ± 11.35 0.55d
Disease duration (median/years) 1–28 (7.0; IQR 3.0–12.8) 1–27 (4.0; IQR 2.0–7.0) 1–35 (7.5; IQR 3.2–14.2) 1–60 (7.0; IQR 3.0–11.7) 1–36 (6.5; IQR 3.2–12.0) 0.36c
Functional class
Class I 15/28 (53.6) 8/15 (53.3) 13/28 (46.4) 22/42 (52.4) 41/96 (42.7) 0.75a
Class II 10/28 (35.7) 6/15 (40) 11/28 (39.3) 17/42 (40.5) 39/96 (40.6) 0.99a
Class III + IV 3/28 (10.7) 1/15 (6.7) 4/28 (14.3) 3/42 (7.1) 16/96 (16.7) 0.53a
Eurodescendent 18/24 (75) 10/13 (76.9) 17/26 (65.4) 28/38 (73.7) 58/79 (73.4) 0.91a
Afrodescendent 6/24 (25) 3/13 (23.1) 9/26 (34.6) 10/38 (26.3) 20/79 (25.3) 0.90a
Tobacco exposure 13/25 (52) 7/12 (58.3) 12/26 (46.1) 16/39 (41.02) 39/87 (44.8) 0.82a
Nodules 2/24 (8.33) 0/13 (0) 4/28 (14.28) 1/37 (2.7) 10/88 (11.36) 0.32a
Sjögren syndrome 1/19 (5.2) 3/11 (27.2) 4/24 (16.6) 16/33 (48.4) 25/75 (33.3) 0.009a
Lung ﬁbrosis 1/22 (4.50) 1/11(9.0) 2/24 (8.3) 5/32 (15.6) 6/72 (8.3) 0.68a
IQR, interquartile range.
a Chi-square.
b Fisher test.
c Kruskal–Wallis test.
d Anova (one way).
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ssociation  between  biomarkers  and  clinical  ﬁndings  in
A patients  and  relatives
able 2 shows demographic and clinical data of RA patients
nd their association with the number of positive biomarkers.
EAM were detected in 34.8% (69/198) of the patients.
atients that were negative for all biomarkers had a lower
requency of EAM (5.8% vs. 17.8%, p = 0.01; OR = 3.25; 95%
I = 1.16–10.66). An increase in the concomitant positivity for
 biomarkers was observed in patients with EAM compared
o patients without it (Table 3). In the one by one analysis
f the different EAM, only the p value for secondary Sjö-
ren syndrome remained signiﬁcant (p = 0.01; OR = 2.73; 95%
I = 1.24–6.08).
Table 4 shows association between demographic, clinical
nd serological data and biomarkers positivity in relatives.
mong the relatives 11.7% (22/197) had arthralgia, and a
igniﬁcant frequency of arthralgia was observed in positive
elatives, regardless of the type of biomarker. Each biomarker
resented signiﬁcant association with the others autoanti-
odies tested (Table 4).
ollow-up  of  positive  relatives
he relatives were followed prospectively for a median time of
 years (range 2–8; IQR = 6–7 years) with biannual evaluations.
t moment, three positive relatives (two women and one man,
ean age 43.3 years) had the diagnosis for RA conﬁrmed; allPlease cite this article in press as: Nass FR, et al. Analysis of four serum 
manifestations in patients and arthralgia in relatives. Rev Bras Reumatol. 
f them with high biomarker titers. Among those relatives,
ne was positive for all 4 biomarkers and his sibling (with RA)
ad high titers of anti-CCP. In addition, seven unaffected rela-
ives with high autoantibody titers and some symptoms ofts, relatives and controls. *Analysis not applicable.
the disease are being followed. Two of them are positive for 4
biomarkers concomitantly, two for 2 biomarkers and three for
one biomarker. None of the other positive relatives for tested
biomarkers had diagnosis criterions for RA.
No RA cases were detected among relatives negatives for
autoantibodies.
Discussion
This is a pioneer study in which four serological biomarkers
were evaluated concomitantly in patients with RA and their
relatives in a Southern Brazilian population. Previous stud-
ies have showed an increased positivity for autoantibodies in
unaffected family members when compared to healthy con-
trol subjects5,17,20,21 and the present results corroborate these
ﬁndings.
Although IgA-RF speciﬁcity for RA is not as high as anti-CCP,
IgA-RF can be detected several years before the symptoms of
the disease, suggesting a primary role of IgA-RF in the patho-
genesis of RA.14 This is a very interesting observation since
in the present study IgA-RF was the biomarker with higher
positivity among relatives. In addition, several relatives were
positive for RF and anti-MCV, but the three relatives that had
conﬁrmed RA were all positive for anti-CCP, reinforcing the
high speciﬁcity (99%) and positive predictive value (99%) for
this autoantibody. Supporting this observation, anti-CCP was
the only biomarker with no signiﬁcantly different titers when
patients and relatives were compared (Fig. 2A).biomarkers in rheumatoid arthritis: association with extra articular
2016. http://dx.doi.org/10.1016/j.rbre.2016.03.001
Regarding the number of positive biomarkers, a previous
study22 showed that most RA patients were positive for the
4 biomarkers simultaneously while relatives usually had just
one antibody, as conﬁrmed in this study. One explanation for
Please cite this article in press as: Nass FR, et al. Analysis of four serum biomarkers in rheumatoid arthritis: association with extra articular
manifestations in patients and arthralgia in relatives. Rev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.03.001
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Table 3 – Extra articular manifestations according to the number of positive biomarkers.
Number of positive biomarkers With  EAM (n = 69)
N (%)
Without EAM (n = 129)
N (%)
p
4 (n = 90) 34 (49.3) 56 (43.4) ns
3 (n = 39) 19 (27.5) 20 (15.5) 0.05
2 (n = 28) 9 (13.1) 19 (14.7) ns
1 (n = 14) 3  (4.3) 11  (8.5) ns
No biomarker (n = 27) 4  (5.8) 23  (17.8) 0.01
EAM, extra articular manifestation; ns, not signiﬁcant.
Note: 3 biomarkers with EAM vs. 3 biomarkers without EAM; p = 0.059; OR = 1.26; 95% CI = 0.70–2.27. No biomarker with EAM vs. No biomarker
without EAM; p = 0.0179; OR = 3.25; 95% IC = 1.16–10.66. Fisher test.
Table 4 – Association between demographic, clinical and serological data and biomarkers positivity in the RA patients
relatives.
IgM-RF+ (n = 16) IgM-RF− (n = 182) p
Euro-descendent 14/16 140/182 0.53a
Afrodescendent 2/16 42/182 0.53a
Tobacco exposure 3/16 54/182 0.56a
Female 13/16 108/182 0.11a
Mean age (years) 40.3 ± 12.3 36.5 ± 15.6 0.34c
Arthralgia 6/16 16/178 0.004a
Anti-CCP+ 5/16 6/182 0.0006a
IgA-RF+ 6/16 23/182 0.01a
Anti-MCV+ 5/16 11/182 0.004a
IgA-RF+ (n = 29) IgA-RF−  (n = 169) p
Euro-descendent 24/29 130/169 0.63a
Afrodescendent 5/29 39/169 0.63a
Tobacco exposure 9/29 48/169 0.77b
Female 17/29 104/169 0.76b
Mean age (years) 40.6 ± 15.4 36.1 ± 15.3 0.15c
Arthralgia 6/29 16/165 0.08b
Anti-CCP+ 4/29 7/169 0.059a
IgM-RF+ 6/29 10/169 0.007b
Anti-MCV+ 7/29 9/169 0.0006b
Anti-CCP+ (n = 11) Anti-CCP−  (n = 187) p
Euro-descendent 9/11 145/187 1.00a
Afrodescendent 2/11 42/187 1.00a
Tobacco exposure 3/11 54/187 1.00a
Female 9/11 112/187 0.37a
Mean age (years) 39.3 ± 15.9 36.6 ± 15.4 0.57c
Arthralgia 4/11 18/183 0.02a
IgM-RF+ 5/11 11/187 0.0006a
IgA-RF+ 4/11 25/187 0.05a
Anti-MCV+ 5/11 11/187 0.0006a
Anti-MCV+ (n = 16) Anti-MCV− (n = 182) p
Euro-descendent 12/16 142/182 0.75a
Afrodescendent 4/16 40/182 0.75a
Tobacco exposure 4/16 53/182 1.00a
Female 14/16 107/182 0.03a
Mean age (years) 33.5 ± 16.9 37.1 ± 15.2 0.37c
Arthralgia 6/16 22/178 0.0006a
Anti-CCP+ 5/16 6/182 <0.0001b
IgM-RF+ 5/16 11/182 0.004a
IgA-RF+ 7/16 22/182 0.002b
a Fisher test.
b Chi-square.
c Unpaired t test.
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his outcome may be the epitope spreading phenomenon that
auses increasing antibody levels just prior to the ﬂare of clin-
cal disease.23
Some studies have suggested that anti-MCV has a com-
arable value to anti-CCP for RA diagnosis, with even higher
ensitivity.24,25 This was not the case in the present study
hen the prevalence, sensitivity and speciﬁcity of anti-MCV
ere lower than those of anti-CCP.
A strong correlation between RA biomarkers has been
reviously disclosed. Poulsom and Charles26 showed a good
orrelation between anti-MCV and anti-CCP and between anti-
CV and IgM-RF, but not between anti-CCP and IgM-RF. We
ound signiﬁcant correlation between all markers, especially
etween anti CCP and anti MCV  and between RF IgA and
gM. This pattern was previously described in ﬁrst RA degree
elatives27 and may be associated with the presence of com-
on  epitopes.
Our casuistic presented a high prevalence of EAMs (34.8%)
hat may be explained by genetic and environmental fac-
ors that inﬂuence the immune reactions leading to their
evelopment.28 We  observed positivity for a higher number of
iomarkers among patients with EAMs, in special secondary
S.
The present results for relatives of RA patients demon-
trated that serological screening is feasible and useful tool
or the screening of those individuals at risk, as emphasized
y other authors.17,21,22 The high prevalence of arthralgia in
elatives positive to any of the four biomarkers highlights this
ypothesis, since some of these relatives (three) have already
volved to full blown RA. All the relatives who developed RA
resented high biomarkers titers; one was positive for all four
iomarkers and had one extra sibling positive for anti-CCP.
mong the other two, one was positive for both anti-CCP and
gM-RF, while the other was only positive for anti-CCP. The
ajority of relatives with autoantibodies who did not develop
he disease so far were positive for just one biomarker. How-
ver this does not rule out the great risk for them to develop
he disease. It is possible that they may posteriorly serocon-
ert to two, three or even more  biomarkers as shown in the
atients with established RA.
Finally, the number of biomarkers was higher in RA
atients with EAMs but it was not linked to duration of
he disease and/or the functional class. On the other hand,
eronegative patients presented less EAMs. High frequency
f arthralgia was observed in positive relatives, regardless of
he biomarker type. Future studies may highlight the fascinat-
ng link between the presence of distinct biomarkers and the
athophysiologic mechanisms of AR.
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